☆ 4.7 Review

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

BIOMARKER RESEARCH (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Review Oncology

PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis

Hongsheng Deng et al.

Summary: To date, there is no approved biomarker for predicting pathological response in neoadjuvant PD-(L)1 blockades treated early-stage NSCLC. However, high PD-L1 expression and high TMB are associated with higher rates of MPR and pCR. The cutoff value of 50% demonstrates better prediction efficacy for MPR than 1%.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

添加到收藏夹

Article Oncology

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

Katherine Pisters et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Editorial Material Oncology

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 e PEARLS/KEYNOTE-091 study

L. Paz-Ares et al.

Summary: This study evaluated the efficacy of adjuvant pembrolizumab compared to placebo in patients with completely resected early-stage non-small cell lung cancer. The results showed that adjuvant pembrolizumab significantly improved disease-free survival in the overall population, but did not reach statistical significance in the PD-L1 expression >= 50% population. Adverse events were more common in the pembrolizumab group compared to the placebo group.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Letter Oncology

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients

Zhen Zhou et al.

Summary: This study investigated the genetic changes between NSCLC patients with different responses to neoadjuvant immunotherapy and discovered potential biomarkers that can predict therapeutic outcomes. The findings suggest that HR pathway gene status could serve as novel indicators for guiding treatment decisions in NSCLC patients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Non-Small Cell Lung Cancer, Version 3.2022

David S. Ettinger et al.

Summary: This passage introduces the recommended management for non-small cell lung cancer (NSCLC) in the NCCN Clinical Practice Guidelines, with a focus on targeted therapies for patients with metastatic NSCLC and actionable mutations.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

Total-body PET/CT-First Clinical Experiences and Future Perspectives

Quinn Kwan-Tai Ng et al.

Summary: The development of total-body PET technology has greatly improved sensitivity and lesion detection, providing several benefits in clinical applications. However, there are also limitations and challenges that need to be addressed.

SEMINARS IN NUCLEAR MEDICINE (2022)

添加到收藏夹

Article Oncology

Cancer treatment and survivorship statistics, 2022

Kimberly D. Miller et al.

Summary: The number of cancer survivors in the United States is increasing due to population growth, aging, and improved detection and treatment. The most prevalent cancers are prostate, skin melanoma, and colon and rectum for males, and breast, uterine corpus, and thyroid for females. Treatment disparities exist, with Black patients being less likely to be diagnosed with early-stage cancer and having lower surgical receipt rates.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Oncology

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Mariano Provencio et al.

Summary: Neoadjuvant chemotherapy plus nivolumab demonstrates effectiveness in resectable non-small cell lung cancer. Pretreatment ctDNA levels significantly correlate with survival outcomes and outperform radiologic assessments in predicting survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O'Brien et al.

Summary: This study evaluated the use of Pembrolizumab as adjuvant therapy for completely resected stage IB-IIIA NSCLC. The results showed that Pembrolizumab significantly improved disease-free survival in both the overall population and the PD-L1 TPS of 50% or greater population.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis

Chao Zhang et al.

Summary: Despite limited efficacy of immunotherapy for advanced non-small-cell lung cancer (NSCLC) with driver mutations, neoadjuvant immunotherapy may be clinically valuable for resectable localized oncogene-mutant NSCLC, especially for EGFR-mutant NSCLC.

NPJ PRECISION ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients

Elliot Naidus et al.

Summary: Durvalumab, an immune checkpoint inhibitor targeting PD-L1, shows promising results in NSCLC patients by increasing the diversity of TCR repertoire, leading to improved overall survival. Patients with greater TCR cluster size and increased diversity after 15 days of durvalumab treatment tend to have longer overall survival, highlighting the potential of early TCR repertoire diversification as a predictive marker for improved survival outcomes in NSCLC patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer

Monika Pradhan et al.

Summary: The advent of immune checkpoint inhibitors has significantly changed the treatment of patients with locally advanced to resectable and metastatic non-small cell lung cancer. While early results of neoadjuvant ICIs in early-stage NSCLC are promising, further research is needed to explore efficacy, resistance mechanisms, and biomarkers for predicting clinical benefit.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data

Ani John et al.

Summary: The study found improved clinical outcomes in patients who were adherent to NCCN-recommended biomarker testing and first-line therapy, highlighting the value of following NCCN guideline recommendations and the need for timely access to biomarker testing and individualized treatment.

ADVANCES IN THERAPY (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Review Medicine, General & Internal

Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement

Alex H. Krist et al.

Summary: Lung cancer is the second most common cancer and leading cause of cancer death in the US, with smoking and increasing age being the primary risk factors. Annual screening with low-dose computed tomography is recommended for adults aged 50 to 80 years with a 20 pack-year smoking history.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

E. A. Rozeman et al.

Summary: The combination of neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma. High tumor mutational burden (TMB) and high interferon-gamma-related gene expression signature score (IFN-gamma score) were associated with pathologic response and a low risk of relapse. These findings support the potential predictive value of TMB and IFN-gamma score in the treatment of melanoma patients.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone et al.

Summary: The NEOSTAR trial showed that neoadjuvant treatment with nivolumab + ipilimumab combination therapy can improve pathologic response rates in operable NSCLC patients and has better clinical efficacy compared to nivolumab alone.

NATURE MEDICINE (2021)

添加到收藏夹

Article Oncology

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

Nasser K. Altorki et al.

Summary: The combination of neoadjuvant durvalumab and stereotactic body radiotherapy in early-stage NSCLC patients shows a high major pathological response rate and is well tolerated, suggesting its potential in treatment, although it comes with certain adverse events.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Preoperative Cardiopulmonary Exercise Test Associated with Postoperative Outcomes in Patients Undergoing Cancer Surgery: A Systematic Review and Meta-Analyses

Daniel Steffens et al.

Summary: The study found a significant association between superior preoperative CPET values, especially peak VO2, and better postoperative outcomes. Other CPET variables also showed positive trends, with no negative trends reported in any of the included studies.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Immunology

Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

Jacob M. Sands et al.

Summary: Non-small-cell lung cancer (NSCLC) causes significant mortality each year. Adjuvant platinum-based chemotherapy improves median overall survival, but many patients still experience disease recurrence. Including pembrolizumab in treatment regimens may improve outcomes for patients.

IMMUNOTHERAPY (2021)

添加到收藏夹

Meeting Abstract Oncology

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

Jonathan Spicer et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

添加到收藏夹

Article Respiratory System

Diastolic Dysfunction Contributes to Impaired Cardiorespiratory Fitness in Patients with Lung Cancer and Reduced Lung Function Following Chest Radiation

Georgia K. Thomas et al.

Summary: Cardiorespiratory fitness is a strong predictor of cardiovascular health and overall mortality. Patients with lung cancer receiving radiotherapy may experience reduced CRF, with diastolic dysfunction and NTproBNP levels inversely correlated with peak VO2. NTproBNP is the strongest independent variable associated with peak VO2 in this population, indicating its significance in predicting CRF.

LUNG (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab

Sergey Gavrilov et al.

Summary: Therapy optimization in advanced non-small cell lung cancer (NSCLC) is a significant challenge. A study used tumor size and neutrophil-to-lymphocyte ratio as longitudinal biomarkers for survival prediction, finding that incorporating longitudinal measurements can improve patient subgrouping and increase the precision of survival estimates. The highest performance was achieved using a multivariate model, enabling predictions of NSCLC clinical outcomes.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)

添加到收藏夹

Article Oncology

Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy

Annikka Weissferdt et al.

CLINICAL LUNG CANCER (2020)

添加到收藏夹

Article Oncology

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Shugeng Gao et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer

Tina Cascone et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

Sacha Rothschild et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Catherine A. Shu et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

Joshua E. Reuss et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer

Qianping Li et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes

Yun Ling et al.

NPJ PRECISION ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Survival Trends of Metastatic Lung Cancer in California by Age at Diagnosis, Gender, Race/Ethnicity, and Histology, 1990-2014

Tianhong Li et al.

CLINICAL LUNG CANCER (2020)

添加到收藏夹

Article Oncology

Predictive value of peripheral lymphocyte counts for immune checkpoint inhibitor efficacy in advanced head and neck squamous cell carcinoma

Jong Chul Park et al.

MOLECULAR AND CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study

T. Karantanos et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement

Chao Zhang et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Correction Oncology

High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer (vol 12, pg 56, 2019)

Wenwu Xiao et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade

Florian Huemer et al.

JOURNAL OF CLINICAL MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Cell Biology

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

Bradon R. McDonald et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer

Matthew J. Bott et al.

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2019)

添加到收藏夹

Review Oncology

Cancer immunoediting and resistance to T cell-based immunotherapy

Jake S. O'Donnell et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Medicine, General & Internal

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events

Yoshiyuki Nakamura

FRONTIERS IN MEDICINE (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer

Chi-Fu Jeffrey Yang et al.

ANNALS OF THORACIC SURGERY (2018)

添加到收藏夹

Article Oncology

Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer

Gavitt A. Woodard et al.

CLINICAL LUNG CANCER (2018)

添加到收藏夹

Article Oncology

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC

A. Lisberg et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

P. M. Forde et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Oncology

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma A Systematic Review and Meta-analysis

Chee Khoon Lee et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Letter Medicine, General & Internal

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Xin Yang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Respiratory System

Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances

Nikhil T. Sebastian et al.

JOURNAL OF THORACIC DISEASE (2018)

添加到收藏夹

Review Oncology

Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity

Orneala Bakos et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Article Oncology

Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas

Won Jin Ho et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Article Medicine, General & Internal

Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study

Marie Warny et al.

PLOS MEDICINE (2018)

添加到收藏夹

Article Respiratory System

Management of stage I and II nonsmall cell lung cancer

Fiona McDonald et al.

EUROPEAN RESPIRATORY JOURNAL (2017)

添加到收藏夹

Article Oncology

EAdjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

Mark G. Kris et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Non-Small Cell Lung Cancer, Version 5.2017 Clinical Practice Guidelines in Oncology

David S. Ettinger et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Long-term pulmonary function after surgery for lung cancer

Naohiro Kobayashi et al.

INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY (2017)

添加到收藏夹

Article Respiratory System

Bronchoscopy with endobronchial ultrasound guided transbronchial needle aspiration vs. transthoracic needle aspiration in lung cancer diagnosis and staging

Mark L. Munoz et al.

JOURNAL OF THORACIC DISEASE (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Validating the Thoracic Revised Cardiac Risk Index Following Lung Resection

Daniel C. Thomas et al.

ANNALS OF THORACIC SURGERY (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Endoscopic Mediastinal Staging in Lung Cancer Is Superior to Gold Standard Surgical Staging

Ilyes Berania et al.

ANNALS OF THORACIC SURGERY (2016)

添加到收藏夹

Article Oncology

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

Justin F. Gainor et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Review Oncology

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Weijie Ma et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)

添加到收藏夹

Review Oncology

The Utility of Exercise Testing in Patients with Lung Cancer

Duc Ha et al.

JOURNAL OF THORACIC ONCOLOGY (2016)

添加到收藏夹

Article Oncology

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

Peter Goldstraw et al.

JOURNAL OF THORACIC ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Exosome-mediated Transfer of αvβ3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype

Amrita Singh et al.

MOLECULAR CANCER RESEARCH (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence

Abhirami A. Ananth et al.

PLOS ONE (2016)

添加到收藏夹

Article Oncology

CD44v6-competent tumor exosomes promote motility, invasion and cancer-initiating cell marker expression in pancreatic and colorectal cancer cells

Zhe Wang et al.

ONCOTARGET (2016)

添加到收藏夹

Article Surgery

Risk Stratification in Lung Resection

Michele Salati et al.

CURRENT SURGERY REPORTS (2016)

添加到收藏夹

Article Oncology

Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis

Julia Kravchenko et al.

LUNG CANCER (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Tumour exosome integrins determine organotropic metastasis

Ayuko Hoshino et al.

NATURE (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Endobronchial Ultrasonography for Positron Emission Tomography and Computed Tomography-Negative Lymph Node Staging in Non-Small Cell Lung Cancer

Masato Shingyoji et al.

ANNALS OF THORACIC SURGERY (2014)

添加到收藏夹

Article Immunology

In vivo suppression of NK cell cytotoxicity by stress and surgery: Glucocorticoids have a minor role compared to catecholamines and prostaglandins

Ella Rosenne et al.

BRAIN BEHAVIOR AND IMMUNITY (2014)

添加到收藏夹

Review Medicine, General & Internal

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

Sarah Burdett et al.

LANCET (2014)

添加到收藏夹

Article Oncology

Preventing Postoperative Metastatic Disease by Inhibiting Surgery-Induced Dysfunction in Natural Killer Cells

Lee-Hwa Tai et al.

CANCER RESEARCH (2013)

添加到收藏夹

Article Critical Care Medicine

Physiologic Evaluation of the Patient With Lung Cancer Being Considered for Resectional Surgery Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Alessandro Brunelli et al.

CHEST (2013)

添加到收藏夹

Article Critical Care Medicine

Methods for Staging Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Gerard A. Silvestri et al.

CHEST (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Evaluation of 2 Real-Time PCR Assays for In Vitro Diagnostic Use in the Rapid and Multiplex Detection of EGFR Gene Mutations in NSCLC

Anthony T. C. Wong et al.

DIAGNOSTIC MOLECULAR PATHOLOGY (2013)

添加到收藏夹

Review Oncology

Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies

Tianhong Li et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non-Small-Cell Lung Cancers

Jamie E. Chaft et al.

JOURNAL OF THORACIC ONCOLOGY (2013)

添加到收藏夹

Review Medicine, General & Internal

Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis

Hesborn Wao et al.

SYSTEMATIC REVIEWS (2013)

添加到收藏夹

Article Oncology

The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment

L. M. Ofiara et al.

CURRENT ONCOLOGY (2012)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Diffusing capacity predicts long-term survival after lung resection for cancer

Mark K. Ferguson et al.

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2012)

添加到收藏夹

Review Surgery

Surgical Trauma and Postoperative Immune Dysfunction

P. Menges et al.

EUROPEAN SURGICAL RESEARCH (2012)

添加到收藏夹

Article Medicine, General & Internal

A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies

Johannes R. Kratz et al.

LANCET (2012)

添加到收藏夹

Article Critical Care Medicine

Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer Quick Reference Chart and Diagrams

Omar Lababede et al.

CHEST (2011)

添加到收藏夹

Article Oncology

Resection of Non-Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System

Andrew V. Kossenkov et al.

CLINICAL CANCER RESEARCH (2011)

添加到收藏夹

Article Oncology

Contemporary Results of Surgical Resection of Non-small Cell Lung Cancer After Induction Therapy A Review of 549 Consecutive Cases

Stephen A. Barnett et al.

JOURNAL OF THORACIC ONCOLOGY (2011)

添加到收藏夹

Review Surgery

Surgery induced immunosuppression

Brian V. Hogan et al.

SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND (2011)

添加到收藏夹

Editorial Material Oncology

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

Stephen B. Edge et al.

ANNALS OF SURGICAL ONCOLOGY (2010)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Recalibration of the Revised Cardiac Risk Index in Lung Resection Candidates

Alessandro Brunelli et al.

ANNALS OF THORACIC SURGERY (2010)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Predictors of Major Morbidity and Mortality After Pneumonectomy Utilizing The Society for Thoracic Surgeons General Thoracic Surgery Database

Mark Shapiro et al.

ANNALS OF THORACIC SURGERY (2010)

添加到收藏夹

Review Oncology

Integrins in cancer: biological implications and therapeutic opportunities

Jay S. Desgrosellier et al.

NATURE REVIEWS CANCER (2010)

添加到收藏夹

Article Surgery

Postoperative Complications After Transthoracic Esophagectomy for Cancer of the Esophagus and Gastroesophageal Junction Are Correlated With Early Cancer Recurrence Role of Systematic Grading of Complications Using the Modified Clavien Classification

Toni Lerut et al.

ANNALS OF SURGERY (2009)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Article Medicine, General & Internal

Preoperative Staging of Lung Cancer with Combined PET-CT.

Barbara Fischer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

Article Oncology

Adjuvant chemotherapy for non-small cell lung cancer

Emilio Bria et al.

JOURNAL OF THORACIC ONCOLOGY (2007)

添加到收藏夹

Review Medicine, General & Internal

Understanding the basics of cardiopulmonary exercise testing

Richard V. Milani et al.

MAYO CLINIC PROCEEDINGS (2006)

添加到收藏夹

Article Surgery

Major abdominal surgery increases plasma levels of vascular endothelial growth factor - Open more so than minimally invasive methods

Avraham Belizon et al.

ANNALS OF SURGERY (2006)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Carbon monoxide lung diffusion capacity improves risk stratification in patients without airflow limitation: evidence for systematic measurement before lung resection

A Brunelli et al.

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2006)

添加到收藏夹

Article Surgery

Increased surgical stress promotes tumor metastasis

Y Tsuchiya et al.

SURGERY (2003)

添加到收藏夹

Article Critical Care Medicine

The physiologic evaluation of patients with lung cancer being considered for resectional surgery

MA Beckles et al.

CHEST (2003)

添加到收藏夹

Article Oncology

New guidelines to evaluate the response to treatment in solid tumors

F Duffaud et al.

BULLETIN DU CANCER (2000)

添加到收藏夹

Article Surgery

Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection

K Yamaguchi et al.

ANNALS OF SURGERY (2000)

添加到收藏夹

Article Oncology

New guidelines to evaluate the response to treatment in solid Tumors

P Therasse et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.